Clinical Commander

Back to dossier
cardio.dvt.behcet-disease.v1PRODUCTION
cardio.dvt.behcet-disease.v1

DVT/VTE in Behçet's disease (variable-vessel vasculitis)

cardiologyacuteadult
Hard-required inputs
0 / 13
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Behçet vascular phenotype: variable-vessel vasculitis with venous predominance; VTE driven by vessel-wall inflammation, NOT a primary coagulation defect; AC alone is insufficient — recurrence ≈40% at 2 y without immunosuppression vs much lower with azathioprine ± steroids per EULAR 2018

Inputs
1
Actions
0
Advance rule
Set
Advance when

vasculitic etiology framed

Patient inputs (14)

Behçet typically presents in 3rd-4th decade; VTE risk concentrates in young adult males — informs pretest probability

Male sex confers higher vascular and ocular morbidity; informs prognosis and immunosuppression aggressiveness

Turkish, Iranian, Mediterranean, Central/East Asian ancestry — HLA-B51 enriched populations; pretest probability for Behçet rises

Major ISG / ICBD criterion — required for diagnosis; documents disease activity

Major ISG / ICBD criterion; informs diagnosis and disease activity scoring

Sight-threatening posterior uveitis is a major Behçet complication and an independent indication for immunosuppression intensification

Inflammatory markers tracking disease activity; target normalisation parallels AC tapering decision

Cardinal symptom of proximal DVT

Initial confirmation of DVT location (proximal vs distal vs vena cava extension)

Baseline platelet for AC initiation; ongoing surveillance during azathioprine and cyclophosphamide therapy

CT-angio chest BEFORE anticoagulation in any Behçet patient with hemoptysis or unexplained dyspnea — pulmonary artery aneurysm is a strict AC contraindication and must be excluded

HAS-BLED + falls + GI bleed history drives indefinite-AC eligibility and informs anticoagulant intensity

eGFR for DOAC dosing and azathioprine/cyclophosphamide dose adjustment

HLA-B51 supports diagnosis (~60% of patients positive in endemic populations); not pathognomonic

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningpulmonary_artery_aneurysm_excludes_anticoagulation_alone
    Behçet patient with hemoptysis or unexplained dyspnea — CT-angio chest reveals pulmonary artery aneurysm; AC alone is contraindicated (paradoxical bleed risk from aneurysm rupture). Immunosuppression must be initiated FIRST
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcerebral_venous_sinus_thrombosis_in_behcet
    Behçet patient with headache, papilledema, or focal neuro deficit — MR-venography confirms CVST. Most common neurovascular complication; requires AC + high-dose steroids + cyclophosphamide induction together
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningbudd_chiari_or_vena_cava_thrombosis_extension
    Behçet patient with abdominal pain + LFT derangement → hepatic Doppler reveals Budd-Chiari, OR proximal DVT extends into vena cava with venous hypertension; both indicate severe vascular disease requiring cyclophosphamide induction and possibly TIPS or vascular intervention
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_vte_on_anticoagulation_alone_without_immunosuppression
    Behçet patient with recurrent DVT/PE despite therapeutic AC because immunosuppression was not added — vasculitic vessel-wall inflammation continues to drive thrombus formation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresight_threatening_posterior_uveitis_or_cns_flare_during_anticoagulation
    Behçet patient on AC + first-line immunosuppression develops sight-threatening posterior uveitis or CNS parenchymal disease — escalate to TNF-α inhibitor; ophthalmology and neurology emergent
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

ENTRYrequiredDrives risk stratification
Loading…

Recommended regimen

Behçet's vascular VTE — anticoagulation co-administered with immunosuppression (EULAR 2018; ACR/VF 2021; Saadoun cohort)
axis: behcet_vascular_phenotype_anticoagulation_plus_immunosuppression
Selected axis "Behçet's vascular VTE — anticoagulation co-administered with immunosuppression (EULAR 2018; ACR/VF 2021; Saadoun cohort)" by default fallback (first axis)
  • apixaban
    first line
    doac_factor_xa_direct
    10 mg BID × 7 d → 5 mg BID • PO • BID indefinite while disease active
    triggers: behcet_peripheral_dvt, no_pulmonary_aneurysm, no_active_bleed, no_triple_positive_aps, egfr_above_25
    AMPLIFY (Agnelli NEJM 2013 PMID 23808982); ACCP 2021; small Behçet case series support DOAC use for routine peripheral DVT
    rxcui 1364430
  • rivaroxaban
    first line
    doac_factor_xa_direct
    15 mg BID × 21 d → 20 mg daily • PO • BID then daily indefinite while disease active
    triggers: behcet_peripheral_dvt, doac_alternative, egfr_above_30
    EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814); alternative DOAC
    rxcui 1114195
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 • SC • BID
    triggers: inpatient_acute_bridge, pregnancy, aps_workup_pending, doac_contraindicated
    ASH 2020 (PMID 33007077); ACCP 2021 — LMWH bridge for inpatient stabilisation and pregnancy
    rxcui 67108
  • warfarin
    second line
    vitamin_k_antagonist
    5 mg daily; INR target 2-3 (target 3 if triple-positive APS coexists) • PO • daily indefinite while disease active
    triggers: concurrent_aps_triple_positive, frequent_ac_interruptions_for_flares, doac_unaffordable
    Easier reversibility for vasculitis flares requiring procedures; preferred when concurrent triple-positive APS
    rxcui 11289
  • azathioprine
    first line
    purine_antimetabolite
    2-3 mg/kg/day PO (TPMT-guided dosing — start lower if intermediate activity) • PO • daily indefinite while disease active
    triggers: behcet_dvt_first_episode, remission_maintenance
    EULAR 2018 (Hatemi PMID 29945920) Class I — azathioprine reduces VTE recurrence dramatically vs AC alone (Saadoun cohort)
    rxcui 1256
  • prednisone
    first line
    glucocorticoid
    1 mg/kg/day PO (max 60-80 mg) tapering over weeks-months as immunosuppression takes effect • PO • daily, tapering
    triggers: acute_vasculitic_flare, co_administer_with_azathioprine_induction
    EULAR 2018 — co-administered glucocorticoid for induction; methylprednisolone 1 g IV × 3 d for severe / sight-threatening
    rxcui 8640
  • cyclophosphamide
    first line
    alkylating_agent
    500-1000 mg/m² IV monthly × 6 mo (NIH protocol) or 2 mg/kg/day PO • IV or PO • monthly × 6 mo
    triggers: vena_cava_thrombosis, cerebral_venous_sinus_thrombosis, pulmonary_artery_aneurysm_with_thrombus, severe_refractory_disease
    EULAR 2018 — cyclophosphamide first-line for severe vascular Behçet (vena cava, CVST, pulmonary aneurysm); monitor for hemorrhagic cystitis (mesna), bone marrow suppression, infertility
    rxcui 3002
  • infliximab
    rescue
    tnf_alpha_inhibitor
    5 mg/kg IV at 0, 2, 6 weeks then every 8 weeks • IV • q8 weeks maintenance
    triggers: refractory_to_azathioprine_plus_steroids, sight_threatening_posterior_uveitis, recurrent_vte_on_first_line_immunosuppression
    EULAR 2018 — TNF-α inhibitors for refractory or sight-threatening Behçet; ACR/VF 2021 strong recommendation; pre-treatment TB and hepatitis screening required
    rxcui 191831
  • adalimumab
    rescue
    tnf_alpha_inhibitor
    40 mg SC every 2 weeks (or weekly for severe disease) • SC • q2 weeks
    triggers: infliximab_alternative, patient_preference_for_subcutaneous
    Alternative TNF-α inhibitor with similar efficacy in vascular Behçet (case series + extension trials)
    rxcui 327361
  • colchicine
    add on
    microtubule_inhibitor
    0.6 mg PO BID-TID • PO • BID-TID indefinite
    triggers: mucocutaneous_baseline_control, recurrent_oral_genital_ulcers
    EULAR 2018 — first-line for mucocutaneous manifestations; baseline anti-inflammatory adjunct in vascular disease
    rxcui 2683

outpatient playbook — drug actions (4)

  1. 1. maintenance apixaban
    rxcui 1364430
    apixaban 5 mg BID OR 2.5 mg BID extended-reduced after first 6 mo if continuing indefinite • PO • BID
    trigger: Indefinite while disease active
    AMPLIFY-EXT (Agnelli NEJM 2013 PMID 23216615); ACCP 2021
  2. 2. maintenance azathioprine
    rxcui 105585
    azathioprine 2-3 mg/kg/day • PO • daily
    trigger: Maintenance
    EULAR 2018
  3. 3. switch to LMWH if pregnancy planned or confirmed
    rxcui 67108
    enoxaparin therapeutic 1 mg/kg BID antepartum + 6 weeks postpartum if active VTE • SC • BID
    trigger: Pregnancy
    ASH 2018 pregnancy PMID 30482767
  4. 4. colchicine for mucocutaneous baseline
    rxcui 2683
    0.6 mg PO BID • PO • BID indefinite
    trigger: Recurrent oral/genital ulcers
    EULAR 2018

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Unilateral leg swelling with proven DVT in patient with recurrent oral aphthae + genital ulcers ± uveitis — pretest probability for vascular Behçet is high (ISG / ICBD criteria); VTE in young (under 40) male of Turkish, Iranian, Mediterranean, or Central/East Asian descent — prompts Behçet workup; HLA-B51 association; Recurrent DVT with elevated CRP/ESR + ocular inflammation or skin pathergy — vasculitic VTE should be considered.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**DVT/VTE in Behçet's disease (variable-vessel vasculitis)** (cardio.dvt.behcet-disease.v1).
Scope: Behçet vascular phenotype: variable-vessel vasculitis with venous predominance; VTE driven by vessel-wall inflammation, NOT a primary coagulation defect; AC alone is insufficient — recurrence ≈40% at 2 y without immunosuppression vs much lower with azathioprine ± steroids per EULAR 2018

No severity triggers fired against current inputs.

Plan

Regimen axis: **Behçet's vascular VTE — anticoagulation co-administered with immunosuppression (EULAR 2018; ACR/VF 2021; Saadoun cohort)**.
1. apixaban 10 mg BID × 7 d → 5 mg BID PO BID indefinite while disease active (doac_factor_xa_direct, first line) — AMPLIFY (Agnelli NEJM 2013 PMID 23808982); ACCP 2021; small Behçet case series support DOAC use for routine peripheral DVT
2. rivaroxaban 15 mg BID × 21 d → 20 mg daily PO BID then daily indefinite while disease active (doac_factor_xa_direct, first line) — EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814); alternative DOAC
3. enoxaparin 1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 SC BID (lmwh, first line) — ASH 2020 (PMID 33007077); ACCP 2021 — LMWH bridge for inpatient stabilisation and pregnancy
4. warfarin 5 mg daily; INR target 2-3 (target 3 if triple-positive APS coexists) PO daily indefinite while disease active (vitamin_k_antagonist, second line) — Easier reversibility for vasculitis flares requiring procedures; preferred when concurrent triple-positive APS
5. azathioprine 2-3 mg/kg/day PO (TPMT-guided dosing — start lower if intermediate activity) PO daily indefinite while disease active (purine_antimetabolite, first line) — EULAR 2018 (Hatemi PMID 29945920) Class I — azathioprine reduces VTE recurrence dramatically vs AC alone (Saadoun cohort)
6. prednisone 1 mg/kg/day PO (max 60-80 mg) tapering over weeks-months as immunosuppression takes effect PO daily, tapering (glucocorticoid, first line) — EULAR 2018 — co-administered glucocorticoid for induction; methylprednisolone 1 g IV × 3 d for severe / sight-threatening
7. cyclophosphamide 500-1000 mg/m² IV monthly × 6 mo (NIH protocol) or 2 mg/kg/day PO IV or PO monthly × 6 mo (alkylating_agent, first line) — EULAR 2018 — cyclophosphamide first-line for severe vascular Behçet (vena cava, CVST, pulmonary aneurysm); monitor for hemorrhagic cystitis (mesna), bone marrow suppression, infertility
8. infliximab 5 mg/kg IV at 0, 2, 6 weeks then every 8 weeks IV q8 weeks maintenance (tnf_alpha_inhibitor, rescue) — EULAR 2018 — TNF-α inhibitors for refractory or sight-threatening Behçet; ACR/VF 2021 strong recommendation; pre-treatment TB and hepatitis screening required
9. adalimumab 40 mg SC every 2 weeks (or weekly for severe disease) SC q2 weeks (tnf_alpha_inhibitor, rescue) — Alternative TNF-α inhibitor with similar efficacy in vascular Behçet (case series + extension trials)
10. colchicine 0.6 mg PO BID-TID PO BID-TID indefinite (microtubule_inhibitor, add on) — EULAR 2018 — first-line for mucocutaneous manifestations; baseline anti-inflammatory adjunct in vascular disease

Setting playbook (outpatient) — Long-term multidisciplinary management: AC + immunosuppression continuation tied to disease activity; annual rheumatology + ophthalmology + cardiology review; family planning; vaccinations; PTS surveillance; cyclophosphamide bladder cancer screen long-term
11. maintenance apixaban apixaban 5 mg BID OR 2.5 mg BID extended-reduced after first 6 mo if continuing indefinite PO BID — Indefinite while disease active (AMPLIFY-EXT (Agnelli NEJM 2013 PMID 23216615); ACCP 2021)
12. maintenance azathioprine azathioprine 2-3 mg/kg/day PO daily — Maintenance (EULAR 2018)
13. switch to LMWH if pregnancy planned or confirmed enoxaparin therapeutic 1 mg/kg BID antepartum + 6 weeks postpartum if active VTE SC BID — Pregnancy (ASH 2018 pregnancy PMID 30482767)
14. colchicine for mucocutaneous baseline 0.6 mg PO BID PO BID indefinite — Recurrent oral/genital ulcers (EULAR 2018)

Non-pharmacologic actions:
- Compression stocking 30-40 mmHg if PTS symptoms
- OCP avoidance lifelong
- Pre-procedure AC management plan documented
- Multidisciplinary handoff card
- Patient carries Behçet diagnosis card with current immunosuppression

AVOID / contraindication checks:
- Absolute_contraindication_AC_in_pulmonary_artery_aneurysm_until_treated_immunosuppression_first (EULAR 2018; Tascilar 2014 cohort)
- Doac_avoid_active_bleeding (FDA labels)
- Doac_avoid_triple_positive_aps_use_warfarin (TRAPS 2018; ISTH 2020)
- Cyclophosphamide_gonadotoxic_offer_fertility_preservation_before_treatment (oncofertility)
- Cyclophosphamide_hemorrhagic_cystitis_use_mesna_and_hydration (NIH protocol)
- Azathioprine_TPMT_test_before_starting_or_use_lower_dose (FDA label)
- Tnf_alpha_inhibitor_screen_TB_HBV_HCV_before_initiation (ACR/VF 2021)
- Decision:behcet_vte_requires_AC_PLUS_immunosuppression_AC_alone_insufficient (EULAR 2018; Saadoun cohort)
- Decision:vena_cava_or_cvst_or_pulmonary_aneurysm_use_cyclophosphamide_first_line (EULAR 2018)
- Decision:duration_of_AC_indefinite_while_disease_active_taper_with_remission (EULAR 2018; ACCP 2021)
- Decision:multidisciplinary_care_rheumatology_cardiology_ophthalmology_required (EULAR 2018)

Monitoring

Regimen monitoring:
- cbc lft creatinine at 2 weeks then monthly during azathioprine titration (FDA label)
- crp esr monthly during active disease (EULAR 2018 disease-activity tracking)
- ophthalmology slit lamp every 3 months for posterior uveitis surveillance (ACR/VF 2021)
- bladder cancer screen yearly after cyclophosphamide cumulative dose (NIH protocol)
- tb qft yearly during tnf alpha inhibitor therapy (ACR/VF 2021)
- pts villalta at 3 6 12 months for post thrombotic syndrome (Kahn Lancet 2014)
- annual AC continuation decision tied to disease activity (EULAR 2018; ACCP 2021)
- pre pregnancy switch cyclophosphamide or warfarin to azathioprine plus LMWH (ASH 2018 pregnancy)

Setting (outpatient) monitoring:
- Annual labs + clinical reassessment
- Annual PTS Villalta
- Annual HAS-BLED
- Annual urinalysis + bladder ultrasound after cumulative cyclophosphamide

Follow-up plan: Long-term rheumatology + cardiology + ophthalmology multidisciplinary care; AC continuation reviewed annually with disease activity; immunosuppression taper as remission achieved; family planning counseling (azathioprine compatible with pregnancy, cyclophosphamide is gonadotoxic — preserve fertility before treatment); vaccinations updated before biologics
- Close-out criterion: multidisciplinary maintenance plan + reproductive counseling documented

Monitoring phase: CBC + LFT + creatinine at 2 weeks then monthly during azathioprine titration (TPMT screen ideal at start); CRP/ESR monthly to track disease activity; ophthalmology follow-up; bleed surveillance; PTS Villalta at 3/6/12 mo; cyclophosphamide cumulative-dose tracking with bladder cancer screen

Disposition

Current setting: outpatient — Long-term multidisciplinary management: AC + immunosuppression continuation tied to disease activity; annual rheumatology + ophthalmology + cardiology review; family planning; vaccinations; PTS surveillance; cyclophosphamide bladder cancer screen long-term

Disposition criteria:
- Indefinite multidisciplinary follow-up; consider AC taper only after sustained remission ≥1-2 years on stable immunosuppression with normalised CRP/ESR

Escalation triggers (move to higher acuity):
- New VTE despite AC + immunosuppression → escalate (biologic if not used; reassess adherence)
- Pregnancy → switch to LMWH + azathioprine
- Major bleed → reverse, hold, reassess indefinite indication tied to disease activity
- New ocular or neuro symptom → emergent multidisciplinary review

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Behçet patient with hemoptysis or unexplained dyspnea — CT-angio chest reveals pulmonary artery aneurysm; AC alone is contraindicated (paradoxical bleed risk from aneurysm rupture). Immunosuppression must be initiated FIRST
- [LIFE_THREATENING] Behçet patient with headache, papilledema, or focal neuro deficit — MR-venography confirms CVST. Most common neurovascular complication; requires AC + high-dose steroids + cyclophosphamide induction together
- [LIFE_THREATENING] Behçet patient with abdominal pain + LFT derangement → hepatic Doppler reveals Budd-Chiari, OR proximal DVT extends into vena cava with venous hypertension; both indicate severe vascular disease requiring cyclophosphamide induction and possibly TIPS or vascular intervention

Citations

- EULAR 2018 Behçet Disease (Hatemi) + ACR/Vasculitis Foundation 2021 Behçet + ACCP/CHEST 2021 (Stevens) for AC duration [PMID:29945920](https://pubmed.ncbi.nlm.nih.gov/29945920/)
- Cited evidence (PMID 30699320) [PMID:30699320](https://pubmed.ncbi.nlm.nih.gov/30699320/)
- Cited evidence (PMID 34352295) [PMID:34352295](https://pubmed.ncbi.nlm.nih.gov/34352295/)
- Cited evidence (PMID 33007077) [PMID:33007077](https://pubmed.ncbi.nlm.nih.gov/33007077/)
- Cited evidence (PMID 30482767) [PMID:30482767](https://pubmed.ncbi.nlm.nih.gov/30482767/)

Last reconciled with current guidelines: 2026-05-15.
References
  • EULAR 2018 Behçet Disease (Hatemi) + ACR/Vasculitis Foundation 2021 Behçet + ACCP/CHEST 2021 (Stevens) for AC duration — PMID:29945920
  • Cited evidence (PMID 30699320) — PMID:30699320
  • Cited evidence (PMID 34352295) — PMID:34352295
  • Cited evidence (PMID 33007077) — PMID:33007077
  • Cited evidence (PMID 30482767) — PMID:30482767